Laurent Pharmaceuticals Inc., a Montréal-based private biopharmaceutical company currently developing a clinical stage lipid modulator (LAU-7b) designed to address the compromised immune-inflammatory response in Cystic Fibrosis (CF), recently announced positive data from its Phase 1b study that assessed LAU-7b in adult patients with CF. LAU-7b is a novel…
cystic fibrosis
Pulmatrix, Inc., a biopharmaceutical company focused on inhaled therapies for serious pulmonary diseases, recently announced a new drug candidate called PUR1900 for the treatment of fungal infections associated with cystic fibrosis (CF). CF is a rare, life-threatening genetic disease in which a defective gene (CFTR) induces a salt imbalance, causing…
The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of those who have had transplants live beyond 10 years, new research has found. The encouraging statistics were published today in the Journal of Heart Lung Transplantation by…
Galapagos NV, a clinical-stage biotechnology company, recently delivered a joint presentation with AbbVie during the 38th annual conference of the European Cystic Fibrosis Society held in Brussels, Belgium. The presentation revealed co-developed technologies to address CF, part of Galapagos’ pipeline that includes three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and…
AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced study results for a trial looking at a novel treatment strategy for cystic fibrosis (CF) patients. The results, which suggested that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa)…
The Cystic Fibrosis Trust recently announced its first-ever appointment of a “Director of Impact” to spearhead the organization’s commitment to improve care, support and research for those with CF in the United Kingdom. Dr. Keith Brownlee boasts a proven record of experience and expertise as a cystic fibrosis specialist pediatrician, having worked for more than 20…
Vertex Pharmaceuticals Incorporated recently announced in a press release new data on its long-term PROGRESS study testing the investigational regimen ORKAMBI (lumacaftor/ivacaftor) for cystic fibrosis (CF). The data was presented at the 38th European Cystic Fibrosis Society (ECFS) Conference, June 10-13, 2015 held in Brussels, Belgium in…
New research is shedding light on a possible link between endometriosis in females who have cystic fibrosis. Cystic fibrosis (CF) is a genetic disorder caused by mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene that mostly affects the lungs, but also the pancreas, liver, kidneys and intestine. The…
Internationally recognized Cystic Fibrosis expert and State University of New York at Buffalo clinical professor of pediatrics Drucy S. Borowitz, MD has received the 2015 Stockton Kimball Award for outstanding scientific achievement and service She accepted the honor at a May 28 SUNY Buffalo School of Medicine and…
The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.